序号 |
标题 |
次数 |
作者 |
发布时间 |
81946 |
6-(苄氧羰基)氨基-3-(甲硫基)-1,2,4-四嗪;6-(benzyloxycarbonyl)amino-3-(methylthio)-1,2,4,5-tetrazine |
108 |
WYQ |
2024-12-03 |
81947 |
6-(乙酰氨基)-3-(甲硫基)-1,2,4-四嗪;6-(acetylamino)-3-(methylthio)-1,2,4,5-tetrazine |
131 |
WYQ |
2024-12-03 |
81948 |
cFLFLFK-PEG-DOTA ;细胞特异性肽-聚乙二醇-DOTA |
77 |
wyh |
2024-12-03 |
81949 |
6-[(叔丁氧基羰基)氨基]-3-(甲硫基)-1,2,4-四嗪;6-[(tert-butyloxycarbonyl)amino]-3-(methylthio)-1,2,4,5-tetrazine |
111 |
WYQ |
2024-12-03 |
81950 |
MMA-DOTA-Cys 61 ,DOTA-马来酰亚胺-半胱氨酸 |
137 |
wyh |
2024-12-03 |
81951 |
DOTA-BR96 ,DOTA标记BR96单克隆抗体 |
110 |
wyh |
2024-12-03 |
81952 |
DOTA-ggNle-cycmsh(hex),内酰胺桥环化肽偶联DOTA |
99 |
wyh |
2024-12-03 |
81953 |
DOTA-sCCK8[Phe2(p-CH2SO3H) ,大环DOTA偶联多肽 |
99 |
wyh |
2024-12-03 |
81954 |
3,6-双(1H-1,2,3,4-四唑-5-基氨基)-1,2,4,5-四嗪(BTATz);3,6-bis(1H-1,2,3,4-tetrazol-5-yl-amino)- 1,2,4,5-tetrazine |
110 |
WYQ |
2024-12-03 |
81955 |
3,3'-偶氮二(6-氨基-1,2,4,5-四嗪)(DAAT);3,3'-azobis(6-amino-1,2,4,5-tetrazine) |
198 |
WYQ |
2024-12-03 |
81956 |
c(DOTA-RGDf),大环螯合剂DOTA环化RGD肽序列 |
109 |
wyh |
2024-12-03 |
81957 |
3,6-双(吡啶-3-基)-1,2,4,5-四嗪(3,3'-吡喃);3,6-bis(pyridin-3-yl)-1,2,4,5-tetrazine (3,3'-pytz) |
114 |
WYQ |
2024-12-03 |
81958 |
3,6-双(2-甲氧基苯基)-1,2-二氢-1,2,4,5-四嗪(2-MDHT);3,6-bis(2-methoxyphenyl)-1,2-dihydro-1,2,4,5-tetrazine |
126 |
WYQ |
2024-12-03 |
81959 |
3,6-二甲基-1,2,4,5-四嗪;3,6-Dimethyl-1,2,4,5-tetrazine |
129 |
WYQ |
2024-12-03 |
81960 |
3,3'-偶氮(6-氨基-1,2,4,5-四嗪);3,3'-Azobis(6-amino-1,2,4,5-tetrazine)(DAAT) |
158 |
WYQ |
2024-12-03 |
81961 |
3,6-d二肼基-1,2,4,5-四嗪(DHT) |
117 |
WYQ |
2024-12-03 |
81962 |
DOTA-D-phe1-Tyr3-奥曲肽 ,Ga-68-DOTA-TATE |
95 |
wyh |
2024-12-03 |
81963 |
DOTA-cCCK,DOTA偶联胆囊收缩素(CCK)受体 |
122 |
wyh |
2024-12-03 |
81964 |
3,6-d氨基-1,2,4,5-四嗪(DATZ) |
110 |
WYQ |
2024-12-03 |
81965 |
3-d氨基-6-(3,5-二甲基乙基吡唑-1-基)-1,2,4,5-四嗪(ADMPT) |
129 |
WYQ |
2024-12-03 |
81966 |
[DOTA]LTT-SS28 ,生长抑素模拟物 |
141 |
wyh |
2024-12-03 |
81967 |
DOTA-minigastrin (CP04) , DOTA-小胃泌素(CP04) |
147 |
wyh |
2024-12-03 |
81968 |
DOTA-rhuEpo ; DOTA-酰肼偶联rhuEpo |
90 |
wyh |
2024-12-03 |
81969 |
1,2,4,5-四嗪 , 化学式:C2H2N4 |
163 |
WYQ |
2024-12-03 |
81970 |
DOTA-Benerotide ;靶向生长抑素受体 |
82 |
wyh |
2024-12-03 |
81971 |
1,2,4,5-Tetrazines by Palladium Catalysis(钯催化1,2,4,5-四嗪的合成) |
93 |
WYQ |
2024-12-03 |
81972 |
5-苯基-1,2,4-三嗪-3-胺为例,为C9H8N4 |
96 |
WYQ |
2024-12-03 |
81973 |
DOTA-PEG-LA-AuNP,DOTA-PEG-硫辛酸修饰纳米金纳米粒子 |
114 |
wyh |
2024-12-03 |
81974 |
3,6-二(吡啶-2-基)-1,2,4,5-四嗪(pytz) |
143 |
WYQ |
2024-12-03 |
81975 |
HYNIC-PEG11-Tz;联肼尼克酰胺-十一聚乙二醇-四嗪;HYNIC-PEG11-Tetrazine |
97 |
WYQ |
2024-12-03 |
81976 |
DOTA-NT肽偶联金纳米粒子 ,DOTA-NT-AuNPs |
92 |
wyh |
2024-12-03 |
81977 |
[Zr-89]Zr-DFO-PEG5-Tz;[Zr-89]Zr-DFO-PEG5-Tetrazine |
99 |
WYQ |
2024-12-03 |
81978 |
MeTz-NOTA-RGD;甲基四嗪-大环配体-多肽 |
136 |
WYQ |
2024-12-03 |
81979 |
DOTA-Tyr(3)-奥曲肽, DOTA-Tyr(3)-Octreotide |
77 |
wyh |
2024-12-03 |
81980 |
AgNPs–pytz(3,6-二(吡啶-2-基)-1,2,4,5-四嗪包覆的银纳米粒子) |
96 |
WYQ |
2024-12-03 |
81981 |
3,6-di(pyridin-2-yl)-1,2,4,5-s-tetrazine (pytz,3,6-二(吡啶-2-基)-1,4-二氢-1,2,4,5-四嗪) |
124 |
WYQ |
2024-12-03 |
81982 |
DOTA-叶酸偶联物,DOTA-Folate |
128 |
wyh |
2024-12-03 |
81983 |
CQDs-DOTA-Yb,镱-DOTA螯合物功能化碳量子点 |
107 |
wyh |
2024-12-03 |
81984 |
3,6-dihydrazino-s-tetrazine (DHT,3,6-二肼基-s-四嗪) |
118 |
WYQ |
2024-12-03 |
81985 |
BCN-PEG-PAMAM ,环丙烷环辛炔-聚乙二醇-聚酰胺 |
105 |
zyl |
2024-12-03 |
81986 |
(DNAZTzDMP)2Ni(H2O)2][NO3]2;3-(3,3'-二硝基氮杂环丁烷)-6-(3,5-二甲基吡唑)四嗪配合物 |
106 |
WYQ |
2024-12-03 |
81987 |
AB1-HLys-DOTA,DOTA偶联阳离子肽 |
98 |
wyh |
2024-12-03 |
81988 |
PAMAM-PEG-CKAAKN 树枝状大分子聚酰胺胺-聚乙二醇-CKAAKN多肽 |
103 |
zyl |
2024-12-03 |
81989 |
(NH2TzDMP)3Ni][NO3]2;3-氨基-6-(3,5-二甲基吡唑)四嗪配合物 |
84 |
WYQ |
2024-12-03 |
81990 |
(DNAZTzDMP)2Co(H2O)2;3-(3,3'-二硝基氮杂环丁烷)-6-(3,5-二甲基吡唑)四嗪配合物 |
121 |
WYQ |
2024-12-03 |